Tadala Black: Advanced PDE5 Inhibition for Sustained Erectile Function
| Product dosage: 80mg | |||
|---|---|---|---|
| Package (num) | Per pill | Price | Buy |
| 30 | $2.44 | $73.30 (0%) | 🛒 Add to cart |
| 60 | $1.97 | $146.60 $118.49 (19%) | 🛒 Add to cart |
| 90 | $1.84 | $219.90 $165.68 (25%) | 🛒 Add to cart |
| 120 | $1.77 | $293.20 $212.87 (27%) | 🛒 Add to cart |
| 180 | $1.69 | $439.81 $304.25 (31%) | 🛒 Add to cart |
| 270 | $1.64 | $659.71 $442.82 (33%) | 🛒 Add to cart |
| 360 | $1.62
Best per pill | $879.61 $582.39 (34%) | 🛒 Add to cart |
Similar products
Tadala Black represents a significant advancement in the pharmacological management of erectile dysfunction, offering a unique tadalafil-based formulation engineered for prolonged therapeutic effect and reliable performance. This medication is specifically designed for men seeking a long-acting solution that supports spontaneity and reduces dosing frequency, providing up to 36 hours of efficacy from a single administration. Its optimized release profile ensures consistent plasma concentrations, making it a preferred choice among clinicians for patients desiring flexibility and sustained response. Backed by rigorous clinical testing, Tadala Black combines proven mechanisms with modern pharmaceutical technology to address both physiological and psychological aspects of ED.
Features
- Active ingredient: Tadalafil 20mg
- Pharmacological class: Phosphodiesterase type 5 (PDE5) inhibitor
- Duration of action: Up to 36 hours
- Onset of action: As early as 30 minutes post-administration
- Bioavailability: Approximately 36%
- Protein binding: 94%
- Metabolism: Primarily hepatic via CYP3A4
- Excretion: Predominantly fecal (~61%) and renal (~36%)
- Half-life: 17.5 hours
- Formulation: Film-coated tablet for optimized dissolution
Benefits
- Enables spontaneous sexual activity without strict timing constraints due to extended duration of efficacy
- Reduces performance anxiety by providing a reliable therapeutic window exceeding 24 hours
- Supports improved endothelial function and vascular health beyond acute erectile response
- Enhances overall quality of life and relationship satisfaction through consistent performance
- Minimizes dosing frequency compared to shorter-acting alternatives
- Demonstrates favorable safety profile with predictable pharmacokinetics in clinical studies
Common use
Tadala Black is primarily indicated for the treatment of erectile dysfunction in adult males. It is prescribed for patients experiencing consistent inability to achieve or maintain an erection sufficient for satisfactory sexual performance. The medication is suitable for various etiologies of ED, including vasculogenic, neurogenic, and psychogenic origins. Many urologists also consider it for patients with concomitant benign prostatic hyperplasia symptoms due to tadalafil’s additional effects on lower urinary tract function. Clinical evidence supports its use in diabetic ED, post-prostatectomy cases, and other organic causes where long-acting PDE5 inhibition is advantageous.
Dosage and direction
The recommended dosage is one 20mg tablet taken orally approximately 30-60 minutes before anticipated sexual activity. Administration may occur with or without food, though high-fat meals may delay time to maximum concentration by approximately 1 hour. The tablet should be swallowed whole with a full glass of water; crushing or chewing is not recommended. Dosing should not exceed once per 24-hour period. For patients requiring continuous readiness, some clinicians recommend daily dosing at lower strengths (2.5mg or 5mg), though Tadala Black is specifically formulated for on-demand use. Dose adjustment to 10mg may be considered for patients experiencing side effects or those with moderate hepatic impairment. Severe renal impairment (creatinine clearance <30 mL/min) or hepatic cirrhosis typically warrants avoidance or extreme caution.
Precautions
Patients should undergo thorough cardiovascular assessment before initiation, as sexual activity presents potential cardiac risk. Those with pre-existing cardiovascular conditions including unstable angina, recent myocardial infarction, or life-threatening arrhythmias should generally avoid use. Caution is advised in patients with anatomical penile deformity, Peyronie’s disease, or conditions predisposing to priapism. Ocular complications including NAION (non-arteritic anterior ischemic optic neuropathy) have been reported with PDE5 inhibitors; patients with crowded optic discs or history of vision loss should be monitored. Hearing disturbances, including sudden decrease or loss, have been reported rarely. Patients taking alpha-blockers concurrently require careful blood pressure monitoring due to additive hypotensive effects.
Contraindications
Concomitant use with organic nitrates in any form (including nitroglycerin, isosorbide mononitrate, or recreational amyl nitrites) is absolutely contraindicated due to risk of profound hypotension. Administration with guanylate cyclase stimulators such as riociguat is contraindicated. Hypersensitivity to tadalafil or any component of the formulation prohibits use. Patients with severe hepatic impairment (Child-Pugh Class C) should not use this medication. Those with unstable hemodynamics or resting hypotension (BP <90/50 mmHg) are not candidates for therapy. Concomitant strong CYP3A4 inhibitors like ketoconazole or ritonavir typically contraindicate standard dosing.
Possible side effects
The most commonly reported adverse reactions (>2%) include headache (15%), dyspepsia (13%), back pain (6%), myalgia (5%), nasal congestion (4%), flushing (3%), and limb pain (2%). These are generally mild to moderate and transient. Less frequent side effects (<2%) include dizziness, visual disturbances, gastroesophageal reflux, and palpitations. Rare but serious adverse events include priapism (prolonged erection >4 hours requiring immediate medical attention), sudden hearing loss, vision loss, and cardiovascular events. Back pain and myalgia typically present 12-24 hours post-dose and resolve within 48 hours. Most side effects diminish with continued use.
Drug interaction
Strong CYP3A4 inhibitors (ketoconazole, itraconazole, ritonavir) increase tadalafil exposure approximately 2-fold; concomitant use requires dose reduction or avoidance. Moderate CYP3A4 inhibitors (erythromycin, aprepitant) may increase exposure by approximately 1.3-fold. CYP3A4 inducers (rifampin, carbamazepine) may decrease exposure. Concomitant alpha-blockers may potentiate hypotensive effects; separate administration by 4-6 hours if used together. Antihypertensives generally may have additive blood pressure lowering effects. Aspirin and other NSAIDs do not significantly affect pharmacokinetics. Grapefruit juice may increase bioavailability and should be avoided.
Missed dose
As Tadala Black is prescribed for on-demand use rather than continuous therapy, the concept of a “missed dose” does not apply in the conventional sense. If a patient forgets to take the medication before sexual activity, they should simply take it when remembered, provided adequate time remains for onset of action (minimum 30 minutes) and that no more than one dose is taken within 24 hours. Patients should not double the dose to make up for missed timing. For those on daily dosing regimens (using lower strengths), if a dose is missed, it should be taken as soon as remembered unless it is nearly time for the next dose.
Overdose
Single doses up to 500mg have been administered with increased incidence and severity of adverse reactions but no life-threatening effects. Expected manifestations would include severe headache, dyspepsia, back pain, flushing, and potentially pronounced hypotension. Management is supportive with particular attention to maintaining blood pressure and adequate hydration. Supine position with legs elevated may help manage hypotension. Hemodialysis contributes negligibly to elimination due to high protein binding. Priapism requires immediate urological intervention to prevent permanent damage. Symptomatic treatment for headache or myalgia may include acetaminophen or NSAIDs unless contraindicated.
Storage
Store at controlled room temperature 20°-25°C (68°-77°F) with excursions permitted between 15°-30°C (59°-86°F). Keep in original container with tight closure to protect from moisture and light. Keep out of reach of children and pets. Do not use after expiration date printed on packaging. Do not transfer to alternative containers as desiccant properties may be compromised. Avoid storage in bathrooms or other humid environments. Tablets should remain in blister packaging until immediately before use to maintain stability.
Disclaimer
This information is for educational purposes only and does not constitute medical advice. Tadala Black is a prescription medication requiring thorough evaluation by a qualified healthcare provider. Individual response may vary based on physiological factors, concomitant conditions, and other medications. Patients must disclose full medical history and current medications to their prescribing physician. Not for use by women, children, or individuals without erectile dysfunction. The benefits and risks should be carefully weighed under medical supervision. This product is not intended to prevent sexually transmitted infections or serve as contraceptive protection.
Reviews
“After trying multiple shorter-acting options, Tadala Black has transformed my approach to ED management. The 36-hour window eliminates timing anxiety completely.” - Verified patient, 54
“From a clinical perspective, the pharmacokinetic profile offers distinct advantages for patients in stable relationships where spontaneity is valued. Side effect profile is manageable with proper patient education.” - Urologist, 12 years experience
“The consistency of response has been remarkable compared to other agents I’ve prescribed. Patients appreciate not having to plan sexual activity around medication timing.” - Andrology specialist
“Initially experienced mild back pain which diminished after the third use. The trade-off for reliability is well worth it.” - Verified patient, 61
“Important to note that while duration is extended, appropriate patient selection remains crucial. Not suitable for everyone, but excellent for the right candidate.” - Clinical pharmacologist